ANDA 75437, held by ScieGen Pharmaceuticals. Cromolyn Sodium.
As of Nov 21, 2026, ANDA 75437 (Cromolyn Sodium), held by ScieGen Pharmaceuticals, was first approved by FDA on Apr 21, 2000, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 21, 2000 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cromolyn Sodium10MG/ML · solution;inhalation | Cromolyn Sodium | Rx |
| Aug 10, 2022 | Supplement 1Manufacturing | Approved | None posted |
| Apr 21, 2000 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters